Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
br Perspectives and challenges Previously the main focus of
2024-08-02

Perspectives and challenges Previously, the main focus of development of adenosine targets for pain was on A1Rs, due to prominent antinociception in multiple preclinical models and preliminary observations in human trials. However, delivery of agonists can be limited by other (e.g. cardiovascular
br ACK signaling partners ACK interacts with and tyrosine
2024-08-02

ACK1 signaling partners ACK1 interacts with and tyrosine phosphorylates many cellular proteins regulating critical cellular processes [11]. While ACK1 shares common intracellular effectors such as AKT with other signaling pathways, it imparts specificity to signaling by phosphorylating effectors
This study was funded and supported
2024-08-02

This study was funded and supported by Tehran University of Medical Sciences and Health Services; and Iran National Science Foundation. Introduction The enzyme acetylcholinesterase (AChE) plays a central role in the signal transduction in the nervous system, hydrolyzing the neurotransmitter acet
br Colabeling evidence for ACh and
2024-08-02

Colabeling evidence for ACh and GABA cotransmission Though functional demonstrations of ACh/GABA cotransmission remain largely limited to the retina and our recent analyses of cortex (Lee et al., 2010, Saunders et al., 2015a, Saunders et al., 2015b), evidence suggestive of ACh/GABA cotransmission
br Free entry equilibrium At stage of the game
2024-08-02

Free entry equilibrium At stage 2 of the game, n ≥ 2 firms simultaneously decide whether or not to enter the industry. Market entry involves a sunk fixed cost f > 0, which we assume cannot be subtracted from the tax base. Our assumption reflects that deductions of market entry costs are often inc
As we previously observed in the NSFT Fukumoto et
2024-08-02

As we previously observed in the NSFT (Fukumoto et al., 2014), the effect of LY341495 in the FST was also inhibited by a 5-HT1A receptor antagonist, indicating the role of the 5-HT1A receptor in the actions of LY341495. Among the 5-HT1A receptors, which exist both presynaptically and postsynapticall
The H N mutation in exon has
2024-08-02

The H373N mutation in exon 6 has not previously been reported [3], [4], [5], [6]; thus, this mutation appears to be a novel mutation. The functional expression study demonstrated that the H373N mutation results in almost complete loss of enzymatic activity. Thus, it is highly likely that the H373N m
AS 101 Later the same group designed and prepared several st
2024-08-02

Later, the same group designed and prepared several Δ16-steroidal C17 benzoazoles and pyrazines and evaluated their CYP17 and 5α-reductase inhibitory activities, binding to and transactivation of the AR, as well as their antiproliferative effects against two human PC cell lines (LNCaP and LAPC4) [18
Interestingly this situation might be changed by the immunol
2024-08-02

Interestingly, this situation might be changed by the immunological context, in particular by the cytokines encountered during differentiation or activation. LPS-activation of bone marrow-derived DCs differentiated in GM-CSF decreases autophagy, CP2, and subsequent activation of CD4+ T cells (Fig. 2
Jesus et al discovered a new
2024-08-02

Jesus et al. discovered a new series of azaindole as Aurora inhibitors through various modification of GSK1070916 (47). They synthesized series from modification of the GSK1070916 and evaluated for in-vitro Aurora-B/INCENP and Aurora-A/TPX2 inhibition assays. Modified hesperetin 48 and 49 showed IC
EPSP analogs were retrieved from PubChem database
2024-08-01

EPSP analogs were retrieved from PubChem database and docking procedure yielded about eight best binding analogs (Fig. 10). The selected molecules were further assessed for their theoretical Ki values using AUTODOCK software version 4. The predicted binding efficiency of retrieved analogs was estima
The AHR potentially enhances IDO expression possibly via cro
2024-08-01

The AHR potentially enhances IDO-expression, possibly via crosstalk with several inflammatory signaling pathways (shown by now for IL6 and ‘signal transducer and activator of transcription’ (STAT) 3, and for NFκB, toll like receptor-pathways) [56,59,60]. IDO metabolizes Trp to kynurenines, which are
Moreover an increase of extracellular calcium stimulates BMP
2024-08-01

Moreover, an increase of extracellular calcium stimulates BMP-2 expression of pulp Difopein via L-type calcium channel and ERK signaling, which can be attenuated by PD98059 and nifedipine . Dental pulp cells expressed little calcium-sensing receptors . immunohistochemistry staining also shows the
PAN induced nephrosis was accompanied by loss of body weight
2024-08-01

PAN-induced nephrosis was accompanied by loss of body weight, decrease of food intake, increase in urine volume and increases in triglycerides and cholesterol levels, which have been reported previously (Natori et al., 1996). Except for urine volume, each one of these measures was improved by A-3069
If overexpression of ADK is sufficient to induce spontaneous
2024-08-01

If overexpression of ADK is sufficient to induce spontaneous seizures, then reduction of ADK in engineered mice should prevent epileptogenesis. The generation of mice with moderately reduced levels of ADK in brain rather than complete ADK deficiency seems to be essential, since several lines of evid
8052 records 147/537 page Previous Next First page 上5页 146147148149150 下5页 Last page